mullberry
Botanicalexperimental
Clinical trial activity
6 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
1
Earliest trial started Nov 30, 2010 (NCT01230268)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- morace
- mullberry
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06636240 | N/A | Nov 1, 2024 | Taipei Medical University |
| NCT06490263 | Phase 1 | May 13, 2024 | Government of China, Peking University |
| NCT05760456 | Phase 3 | Mar 15, 2023 | Hanoi Medical University |
| NCT05856578 | Phase 4 | Mar 15, 2022 | Nanjing Medical University |
| NCT04258501 | N/A | Nov 24, 2011 | Lambda Therapeutic Research Ltd, Unilever |
| NCT01230268 | N/A | Nov 30, 2010 | Catholic University of Korea, Government of Korea |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Catholic University of Korea | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Government of China | Government | 1 | 1 | 1 | 2024 |
| Government of Korea | Government | 1 | 0 | 1 | 2010 |
| Hanoi Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Lambda Therapeutic Research Ltd | For profit | 1 | 0 | 1 | 2011 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Taipei Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Unilever | For profit | 1 | 1 | 1 | 2011 |
9 organizations
Page 1 / 1